BIT225: Preliminary Phase Ib/IIa data

Biotron said preliminary data from a Thai Phase Ib/IIa trial in 21 treatment-naïve patients with HIV infection showed that twice-daily 400 mg BIT225 for 10 days is capable of significantly reducing HI...